AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

6 stories found

A miniature patient moves through clinic, pharmacy, and payment gates while an oversized platform hand redirects the healthcare pathway.
Social good & healthGlobal+3 clusters01

Consumer AI is becoming healthcare's front door and traffic controller

A peer-reviewed Nature Health Perspective argues that consumer health AI is shifting from an information tool toward control of the care pathway. Major platforms are connecting health-oriented language models to medical records, appointment booking, pharmacy fulfilment, payments, and clinical workflows. The paper examines ChatGPT Health, Amazon Health AI, Ant Group's Afu, and Claude for Healthcare, and says public-health importance increasingly depends on platform integration depth rather than model performance alone. Deeper integration could help patients complete care, especially where services are fragmented or resource constrained. It can also concentrate triage power and create new asymmetries in data and operational control. The proposed accountability framework focuses on evaluation, procurement, routing transparency, data governance, and exit options. Regulators should follow the entire pathway: who interprets symptoms, ranks providers, sees the record, takes payment, and lets a patient leave.

5 min
An empty operating room with a transparent clinical checklist faces an illuminated semiconductor fabrication plant beyond glass.
Social good & healthSouth Korea / Global+3 clusters02

AI chips are minting profit. Surgical AI still has a much thinner evidence base

Two numbers in today's sources deserve to be held side by side without pretending they belong to the same transaction. Samsung's preliminary guidance puts third-quarter operating profit at 107.4 trillion won, nearly nine times the year-earlier figure, as demand and prices for AI-related memory support earnings. These are projected company results, with a detailed divisional breakdown due later; they do not measure the social value delivered by every AI application. Separately, a peer-reviewed scoping review in npj Digital Surgery searched five databases and identified 3,020 records on intraoperative AI clinical decision support. Only five studies met its specific inclusion criteria: one completed feasibility study and four ongoing prospective studies or registries. That does not mean only five AI-in-surgery studies exist, and it does not show these systems are unsafe. It means the prospective clinical and ethical evidence under this review's narrow question remains early. The contrast is about timing and incentives. Markets can reward the infrastructure that makes AI possible long before clinical systems have demonstrated safety, equity, consent and real patient benefit under routine conditions. A chip supplier is not responsible for conducting every surgical trial, and clinical validation properly takes longer than a quarterly earnings report. Still, the scale of investment creates a public expectation: buyers and hospitals should demand prospective outcomes and override procedures before live recommendations influence care. The impressive profit is real as a company forecast. The patient benefit is a separate question that must be tested.

7 min
An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters03

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min
A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters04

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
A paper-collage classroom balances an AI tutor and automated grading stamps against a protected teacher-student conversation.
Cognition & learningUnited States+5 clusters05

AI enters classrooms as educators fight to preserve human connection

WCAX reports that schools are testing AI-driven tutoring and automated grading to personalize learning while navigating academic integrity and the possible loss of human connection. The tradeoff cannot be reduced to adoption versus prohibition. A tutor that gives immediate feedback may expand access, and an assistant that handles routine grading may return time to teachers. The same system can make confident mistakes, expose student data, reward answer production over understanding, or shift professional judgment from an educator to a vendor. Schools need evidence about learning outcomes, not only engagement or time saved. They also need clear rules for disclosure, privacy, age-appropriate use, independent assessment, and the teacher's right to override the tool. The safest classroom is not the one with the least technology. It is the one where AI strengthens human teaching without replacing the struggle, trust, and relationship through which students actually learn.

5 min
Law & informationGlobal+1 clusters06

Owens et al., “Patient Perspectives on AI-Drafted Electronic Portal Messages”

This Duke/NYU-linked qualitative study of 40 patients finds that patients value AI-drafted portal replies mainly for efficiency, but their acceptance is conditional on clinician review, accountability, and disclosure. Patients did not uniformly want “more empathy”; they wanted tone, length, and detail to match the stakes of the message, with lower-stakes refills treated differently from serious clinical concerns.

2 min